Jump to content

Tumor suppressor gene: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m [Pu405]Tweak: title. You can use this bot yourself. Report bugs here.
Tag: repeating characters
Line 2: Line 2:


==Two-hit hypothesis==
==Two-hit hypothesis==
'''Unlike oncogenes''', tumor suppressor genes generally follow the '[[two-hit hypothesis]]', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is because if only one allele for the gene is damaged, the second can still produce the correct protein. In other words, mutant tumor suppressors alleles are usually [[Dominance relationship|recessive]] whereas mutant oncogene alleles are typically [[Dominance relationship|dominant]]. The two-hit hypothesis was first proposed by A.G. Knudson for cases of [[retinoblastoma]].<ref>{{cite journal|author=Knudson AG|title=Mutation and Cancer: Statistical Study of Retinoblastoma|journal=Proc Natl Acad of Sci|volume=68|issue=4|pages=820–3|year=1971|pmid=5279523|doi=10.1073/pnas.68.4.820|pmc=389051}}</ref> Knudson observed that the age of onset of retinoblastoma followed [[Rate_equation#Second-order_reactions|2nd order kinetics]], implying that two independent genetic events were necessary. He recognized that this was consistent with a recessive mutation involving a single gene, but requiring biallelic mutation. [[Oncogene]] mutations, in contrast, generally involve a single allele because they are gain-of-function mutations. There are notable exceptions to the 'two-hit' rule for tumor suppressors, such as certain mutations in the [[p53 (protein)|p53 gene product]]. p53 mutations can function as a 'dominant negative', meaning that a mutated p53 protein can prevent the function of normal protein from the un-mutated allele.<ref>{{cite journal|author=Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B.|title=Suppression of human colorectal carcinoma cell growth by wild-type p53|journal=Science|volume=249|issue=4971|pages=912–5|year=1990|pmid= 2144057|doi=10.1126/science.2144057}}</ref> Other tumor-suppressor genes that are exceptions to the 'two-hit' rule are those that exhibit [[haploinsufficiency]] for example PTCH in medulloblastoma. An example of this is the [[p27 (gene)|p27Kip1]] cell-cycle inhibitor, in which mutation of a single allele causes increased carcinogen susceptibility.<ref>{{cite journal|author=Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ|title=The murine gene p27Kip1 is haplo-insufficient for tumour suppression|journal=Nature|volume=396|issue=6707|pages=177–80|year=1998|pmid=9823898|doi=10.1038/24179}}</ref>
'''Unlike oncogenes''', tumor suppressor genes generally follow the '[[two-hit hypothesis]]', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is because if only one allele for the gene is damaged, the second can still produce the correct protein. In other words, mutant tumor suppressors alleles are usually [[Dominance relationship|recessive]] whereas mutant oncogene alleles are typically [[Dominance relationship|dominant]]. The two-hit hypothesis was first proposed by A.G. Knudson for cases of [[retinoblastoma]].<ref>{{cite journal|author=Knudson AG|title=Mutation and Cancer: Statistical Study of Retinoblastoma|journal=Proc Natl Acad of Sci|volume=68|issue=4|pages=820–3|year=1971|pmid=5279523|doi=10.1073/pnas.68.4.820|pmc=389051}}</ref> Knudson observed that the age of onset of retinoblastoma followed [[Rate_equation#Second-order_reactions|2nd order kinetics]], implying that two independent genetic events were necessary. He recognized that this was consistent with a recessive mutation involving a single gene, but requiring biallelic mutation. [[Oncogene]] mutations, in confdhbskldfjghsltrast, generally involve a single allele because they are gain-of-function mutations. There are notable exceptions to the 'two-hit' rule for tumor suppressors, such as certain mutations in the [[p53 (protein)|p53 gene product]]. p53 mutations can function as a 'dominant negative', meaning that a mutated p53 protein can prevent the function of normal protein from the un-mutated allele.<ref>{{cite journal|author=Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B.|title=Suppression of human colorectal carcinoma cell growth by wild-type p53|journal=Science|volume=249|issue=4971|pages=912–5|year=1990|pmid= 2144057|doi=10.1126/science.2144057}}</ref> Other tumor-suppressor genes that are exceptions to the 'two-hit' rule are those that exhibit [[haploinsufficiency]] for example PTCH in medulloblastoma. An example of this is the [[p27 (gene)|p27Kip1]] cell-cycle inhibitor, in which mutation of a single allele causes increased carcinogen susceptibility.<ref>{{cite journal|author=Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ|title=The murine gene p27Kip1 is haplo-insufficient for tumour suppression|journal=Nature|volume=396|issue=6707|pages=177–80|year=1998|pmid=9823898|doi=10.1038/24179}}</ref>


==Functions==
==Functions==

Revision as of 14:05, 3 October 2011

A tumor suppressor gene, or anti-oncogene, is a gene that protects a cell from one step on the path to cancer. When this gene is mutated to cause a loss or reduction in its function, the cell can progress to cancer, usually in combination with other genetic changes.

Two-hit hypothesis

Unlike oncogenes, tumor suppressor genes generally follow the 'two-hit hypothesis', which implies that both alleles that code for a particular gene must be affected before an effect is manifested. This is because if only one allele for the gene is damaged, the second can still produce the correct protein. In other words, mutant tumor suppressors alleles are usually recessive whereas mutant oncogene alleles are typically dominant. The two-hit hypothesis was first proposed by A.G. Knudson for cases of retinoblastoma.[1] Knudson observed that the age of onset of retinoblastoma followed 2nd order kinetics, implying that two independent genetic events were necessary. He recognized that this was consistent with a recessive mutation involving a single gene, but requiring biallelic mutation. Oncogene mutations, in confdhbskldfjghsltrast, generally involve a single allele because they are gain-of-function mutations. There are notable exceptions to the 'two-hit' rule for tumor suppressors, such as certain mutations in the p53 gene product. p53 mutations can function as a 'dominant negative', meaning that a mutated p53 protein can prevent the function of normal protein from the un-mutated allele.[2] Other tumor-suppressor genes that are exceptions to the 'two-hit' rule are those that exhibit haploinsufficiency for example PTCH in medulloblastoma. An example of this is the p27Kip1 cell-cycle inhibitor, in which mutation of a single allele causes increased carcinogen susceptibility.[3]

Functions

Tumor-suppressor genes, or more precisely, the proteins for which they code, either have a dampening or repressive effect on the regulation of the cell cycle or promote apoptosis, and sometimes do both. The functions of tumor-suppressor proteins fall into several categories including the following:[4]

  1. Repression of genes that are essential for the continuing of the cell cycle. If these genes are not expressed, the cell cycle does not continue, effectively inhibiting cell division.
  2. Coupling the cell cycle to DNA damage. As long as there is damaged DNA in the cell, it should not divide. If the damage can be repaired, the cell cycle can continue.
  3. If the damage cannot be repaired, the cell should initiate apoptosis (programmed cell death) to remove the threat it poses for the greater good of the organism.
  4. Some proteins involved in cell adhesion prevent tumor cells from dispersing, block loss of contact inhibition, and inhibit metastasis. These proteins are known as metastasis suppressors.[5][6]
  5. DNA repair proteins are usually classified as tumor suppressors as well, as mutations in such their genes increase the risk of cancer, for example mutations in HNPCC, MEN1 and BRCA. Furthermore, increased mutation rate from decreased DNA repair leads to increased inactivation of other tumor suppressors and activation of oncogenes.[7]

Examples

The first tumor-suppressor protein discovered was the Retinoblastoma protein (pRb) in human retinoblastoma; however, recent evidence has also implicated pRb as a tumor-survival factor.

Another important tumor suppressor is the p53 tumor-suppressor protein encoded by the TP53 gene. Homozygous loss of p53 is found in 70% of colon cancers, 30–50% of breast cancers, and 50% of lung cancers. Mutated p53 is also involved in the pathophysiology of leukemias, lymphomas, sarcomas, and neurogenic tumors. Abnormalities of the p53 gene can be inherited in Li-Fraumeni syndrome (LFS), which increases the risk of developing various types of cancers.

PTEN acts by opposing the action of PI3K, which is essential for anti-apoptotic, pro-tumorogenic Akt activation.

Other examples of tumor suppressors include APC, CD95, ST5, YPEL3, ST7, and ST14.

See also

References

  1. ^ Knudson AG (1971). "Mutation and Cancer: Statistical Study of Retinoblastoma". Proc Natl Acad of Sci. 68 (4): 820–3. doi:10.1073/pnas.68.4.820. PMC 389051. PMID 5279523.
  2. ^ Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. (1990). "Suppression of human colorectal carcinoma cell growth by wild-type p53". Science. 249 (4971): 912–5. doi:10.1126/science.2144057. PMID 2144057.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998). "The murine gene p27Kip1 is haplo-insufficient for tumour suppression". Nature. 396 (6707): 177–80. doi:10.1038/24179. PMID 9823898.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Sherr CJ (2004). "Principles of tumor suppression". Cell. 116 (2): 235–46. doi:10.1016/S0092-8674(03)01075-4. PMID 14744434. {{cite journal}}: Unknown parameter |month= ignored (help)
  5. ^ Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW (2000). "Metastasis-suppressor genes: a review and perspective on an emerging field". J. Natl. Cancer Inst. 92 (21): 1717–30. doi:10.1093/jnci/92.21.1717. PMID 11058615. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Hirohashi S, Kanai Y (2003). "Cell adhesion system and human cancer morphogenesis". Cancer Sci. 94 (7): 575–81. doi:10.1111/j.1349-7006.2003.tb01485.x. PMID 12841864.
  7. ^ Markowitz S (2000). "DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers". J. Clin. Oncol. 18 (21 Suppl): 75S–80S. PMID 11060332. {{cite journal}}: Unknown parameter |month= ignored (help)

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tumor_suppressor_gene&oldid=453700668"